BeOne Medicines Ltd.

ISIN US07725L1026

 | 

WKN A1437N

Market cap (in EUR)
35,355 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Switzerland

Financials

Key metrics

Market capitalisation, EUR 35,355 m
EPS, EUR 0.47
P/B ratio 8.9
P/E ratio 637.6
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 3,524 m
Net income, EUR -596 m
Profit margin -16.92%

What ETF is BeOne Medicines Ltd. in?

There are 2 ETFs which contain BeOne Medicines Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of BeOne Medicines Ltd. is the L&G Pharma Breakthrough UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.89%
Equity
United States
Health Care
Biotech
44
L&G Pharma Breakthrough UCITS ETF 2.63%
Equity
World
Health Care
Innovation
16
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.